Literature DB >> 18182621

Visualizing length of survival in time-to-event studies: a complement to Kaplan-Meier plots.

Patrick Royston1, Mahesh K B Parmar, Douglas G Altman.   

Abstract

Because of censoring, standard methods of plotting individual survival times are invalid. Therefore, graphic display of time-to-event data usually takes the form of a Kaplan-Meier survival plot. Kaplan-Meier plots, however, make differences between groups seem larger than they really are. To overcome these limitations, we developed a technique for producing scatter plots with survival data and applied it to data from a randomized trial of patients with renal cancer. As of June 21, 2001, 25 of the 347 patients with kidney cancer in the Medical Research Council RE01 randomized treatment trial for whom data were available had been censored, and the remainder had died. Values of the censored survival times were imputed by assuming a log-normal distribution in survival times and by drawing a random sample given that that each patient with censored data survived at least to the point of censoring. The combined original and imputed data were then examined by use of dot plots and scatter plots. In the RE01 trial, median survival of patients treated with interferon was 3.0 months (95% confidence interval = 0.3 to 5.5 months) longer than that in patients treated with medroxyprogesterone acetate. The Kaplan-Meier analysis showed clear separation between treatment groups and between prognostic groups. In contrast, comparisons of individual observed and imputed survival times between groups of patients showed considerable overlap and gave a more realistic idea of the modest between-group differences than Kaplan-Meier comparisons. These graphs of the distribution of survival times for individuals in each study group, which are simple to produce, may usefully complement Kaplan-Meier plots.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18182621     DOI: 10.1093/jnci/djm265

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  10 in total

Review 1.  Biomarkers and surrogate end points--the challenge of statistical validation.

Authors:  Marc Buyse; Daniel J Sargent; Axel Grothey; Alastair Matheson; Aimery de Gramont
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

2.  Avoiding Pitfalls in the Statistical Analysis of Heterogeneous Tumors.

Authors:  David E Axelrod; Naomi Miller; Judith-Anne W Chapman
Journal:  Biomed Inform Insights       Date:  2009-01-01

3.  Novel Risk Modeling Approach of Atrial Fibrillation With Restricted Mean Survival Times: Application in the Framingham Heart Study Community-Based Cohort.

Authors:  Laila Staerk; Sarah R Preis; Honghuang Lin; Juan P Casas; Kathryn Lunetta; Lu-Chen Weng; Christopher D Anderson; Patrick T Ellinor; Steven A Lubitz; Emelia J Benjamin; Ludovic Trinquart
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-03-31

Review 4.  Reporting of loss to follow-up information in randomised controlled trials with time-to-event outcomes: a literature survey.

Authors:  Elke Vervölgyi; Mandy Kromp; Guido Skipka; Ralf Bender; Thomas Kaiser
Journal:  BMC Med Res Methodol       Date:  2011-09-21       Impact factor: 4.615

5.  Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  BMC Med Res Methodol       Date:  2013-12-07       Impact factor: 4.615

6.  End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.

Authors:  Antje Hoering; Brian Durie; Hongwei Wang; John Crowley
Journal:  Future Oncol       Date:  2017-04-11       Impact factor: 3.404

7.  Proposals on Kaplan-Meier plots in medical research and a survey of stakeholder views: KMunicate.

Authors:  Tim P Morris; Christopher I Jarvis; William Cragg; Patrick P J Phillips; Babak Choodari-Oskooei; Matthew R Sydes
Journal:  BMJ Open       Date:  2019-09-30       Impact factor: 2.692

8.  A Novel Early-Stage Lung Adenocarcinoma Prognostic Model Based on Feature Selection With Orthogonal Regression.

Authors:  Binhua Tang; Yuqi Wang; Yu Chen; Ming Li; Yongfeng Tao
Journal:  Front Cell Dev Biol       Date:  2021-01-08

9.  Engagement With a Behavior Change App for Alcohol Reduction: Data Visualization for Longitudinal Observational Study.

Authors:  Lauren Bell; Claire Garnett; Tianchen Qian; Olga Perski; Elizabeth Williamson; Henry Ww Potts
Journal:  J Med Internet Res       Date:  2020-12-11       Impact factor: 5.428

10.  Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes.

Authors:  Harry Hemingway; Peter Croft; Pablo Perel; Jill A Hayden; Keith Abrams; Adam Timmis; Andrew Briggs; Ruzan Udumyan; Karel G M Moons; Ewout W Steyerberg; Ian Roberts; Sara Schroter; Douglas G Altman; Richard D Riley
Journal:  BMJ       Date:  2013-02-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.